These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, {"type":"clinical-trial","attrs":{"text":"NCT00000620","term_id":"NCT00000620"}}NCT00000620.) 